-
Citi Upgrades NantKwest (NK) to Neutral
-
Biotech's Soon-Shiong hiring bankers for Nant cancer drug IPO
-
Pre-Open Movers 05/16: (AKBA) (ETSY) (SINA) Higher; (PTX) (DKS) (SSYS) Lower (more...)
-
Citi Downgrades NantKwest (NK) to Sell
-
NantKwest Announces Presentations at Upcoming Investment Conference Meetings
-
Notable Analyst Rating Changes 10/28: (TWTR) (AAPL) (MAS) Upgraded; (FIVE) (MRVL) (SBLK) Downgraded
-
Citi Starts NantKwest (NK) at Buy
-
NantKwest Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
NantKwest (NK) IPO Opens Up 48%
-
NantKwest (NK) IPO Prices at $25, Above Expected Range
-
NantKwest Announces Pricing of Initial Public Offering

